3.72
前日終値:
$3.84
開ける:
$3.85
24時間の取引高:
1.49M
Relative Volume:
0.68
時価総額:
$247.88M
収益:
$80.00M
当期純損益:
$-76.12M
株価収益率:
-3.2447
EPS:
-1.1465
ネットキャッシュフロー:
$-63.88M
1週間 パフォーマンス:
-0.27%
1か月 パフォーマンス:
+0.81%
6か月 パフォーマンス:
-62.76%
1年 パフォーマンス:
-46.24%
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
FULC
Fulcrum Therapeutics Inc
|
3.72 | 243.88M | 80.00M | -76.12M | -63.88M | -1.1465 |
|
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | JP Morgan | Overweight |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-07-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | ダウングレード | Stifel | Buy → Hold |
| 2024-09-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-09-25 | 開始されました | Goldman | Neutral |
| 2023-08-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | アップグレード | Stifel | Hold → Buy |
| 2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
| 2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 開始されました | Goldman | Buy |
| 2022-03-08 | 開始されました | Oppenheimer | Outperform |
| 2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-16 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
Insider Sell Alert: Alan Ezekowitz Sells 18,000 Shares of Fulcru - GuruFocus
Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan - Stock Titan
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Price to sales forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit - Yahoo Finance
[144] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan
Fulcrum Therapeutics, Inc. Actuals & Estimates (NASDAQ:FULC) - TradingView
EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan
EcoR1 Capital (FULC) reports shared control of 6.0M shares; 9.0% stake - Stock Titan
Fulcrum Therapeutics Shareholders Reaffirm Board and Governance Structure - TipRanks
Fulcrum Therapeutics (FULC) details 2026 stockholder voting on directors and key proposals - Stock Titan
Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey
Fulcrum Therapeutics (FULC) Advances 1.8% as Shares Test Resistance Near $4.12Growth ETF - dars.gov.et
Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fulcrum plunges after discontinuing lead program - MSN
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securiti - The National Law Review
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-06-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out | NDAQ:FULC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations - NewMediaWire
Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fulcrum Therapeutics Inc (FULC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations - NewMediaWire
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewir - The National Law Review
Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fulcrum Therapeutics Inc (FULC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-15 | Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:FULC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - ACCESS Newswire
What's going on with Fulcrum Therapeutics stock on Thursday? - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. Files Form 8-K Report with SEC – Company Information and Key Details (June 2026) - Minichart
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Fulcrum Therapeutics Advances Restructuring with Leadership Changes - TipRanks
Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart - Stock Titan
Fulcrum Therapeutics, Inc. Announces Departure of Greg Tourangeau, Principal Accounting Officer - marketscreener.com
A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Tang entities report 5,451,800‑share stake in Fulcrum (FULC) - Stock Titan
FULC stock crashes as cancer risk forces its only drug program's end - MSN
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):